On February 6, the reporters came to the manufacturing shop of drug production base for export that was opened by the Yichang Ren Fu Pharm with the investment of more than 0.7 billion, through the bright airtight ground glass window, they saw that on the shiny dustproof floor, each world’s most advanced equipment was stood orderly, each worker in white coveralls was busy in their jobs meticulously and methodically.
At the beginning of New Year, the production work was busy, the good news also followed one by one. It was learnt that during the Spring Festival, the company received the spot inspection report, issued by the American FDA, which identified that the oral solid preparation workshop of Yichang Ren Fu Pharm(export base was called for short below)passed the FDA’s spot quality inspection with the zero defect. According to this inspection report, the export base met the American drug specifications so that it passed the American FDA identification. Thus Yichang Ren Fu Pharm became the first pharmaceutical enterprise of producing the oral solid preparation passing the American FDA’s identification in Hubei Province as well.
The export base of Yichang Ren Fu Pharm, one of its three large production zone, located in the Yichang biological industrial park, mainly produces dosage form like drugs tablets and thehardcapsule intended to be exported to European and American markets with the designed capacity of 5 billion grains per year.
At present, The export base of Yichang Ren Fu Pharm has started the drug’s development and research as well as the production aiming at the international frontier market, and started the delivery to the American clients. This time the oral solid preparation passing the American FDA’s identification perfectly would lay the foundation for the company’s expansion of the management scope and the product structure optimization, and would bring the positive influence on expanding the preparation market for the company. (Journalist: Li Pengfei, Correspondents: Chen Xiaojun and Chen Ran)